tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amplia Therapeutics Raises $22.3 Million to Advance Cancer Drug Trials

Story Highlights
Amplia Therapeutics Raises $22.3 Million to Advance Cancer Drug Trials

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Amplia Therapeutics ( (AU:ATX) ) is now available.

Amplia Therapeutics Limited has successfully raised approximately $22.3 million through the issuance of 96,804,354 fully paid ordinary shares. This capital will support the ongoing development of their lead drug candidate, narmafotinib (AMP945), which is currently undergoing a Phase 2a trial for pancreatic cancer. The ACCENT trial, exploring the efficacy of narmafotinib in combination with standard chemotherapy, aims to provide insights into the drug’s potential benefits for patients with advanced pancreatic cancer. This development underscores Amplia’s commitment to advancing treatment options for fibrotic cancers and enhancing its position in the pharmaceutical industry.

More about Amplia Therapeutics

Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF).

Average Trading Volume: 6,873,508

Technical Sentiment Signal: Buy

Current Market Cap: A$95.47M

See more insights into ATX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1